<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isotretinoin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isotretinoin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isotretinoin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8582" href="/d/html/8582.html" rel="external">see "Isotretinoin: Drug information"</a> and <a class="drug drug_patient" data-topicid="10777" href="/d/html/10777.html" rel="external">see "Isotretinoin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708957"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Isotretinoin can cause severe, life-threatening birth defects and is contraindicated in pregnancy. Isotretinoin must not be used by patients who are or may become pregnant. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking isotretinoin in any amount, even for short periods of time. Potentially, any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected.</p>
<p style="text-indent:-2em;margin-left:2em;">Birth defects that have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, CNS, cardiovascular system, and thymus and parathyroid glands. Cases of intelligence quotient (IQ) scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">Documented external abnormalities include skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities include CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases, death has occurred with some of the abnormalities previously noted.</p>
<p style="text-indent:-2em;margin-left:2em;">If pregnancy does occur during treatment of a patient who is taking isotretinoin, isotretinoin must be discontinued immediately and the patient should be referred to an obstetrician-gynecologist experienced in reproductive toxicity for further evaluation and counseling.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Special prescribing requirements:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because of isotretinoin's teratogenicity and to minimize fetal exposure, isotretinoin is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This REMS is called iPLEDGE. Isotretinoin must only be prescribed by prescribers who are enrolled and activated with the iPLEDGE REMS. Isotretinoin must only be dispensed by a pharmacy enrolled and activated with iPLEDGE, and must only be dispensed to patients who are enrolled and meet all the requirements of iPLEDGE.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F185177"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Absorica;</li>
<li>Absorica LD;</li>
<li>Accutane;</li>
<li>Amnesteem;</li>
<li>Claravis;</li>
<li>Myorisan [DSC];</li>
<li>Zenatane</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867283"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Absorica LD;</li>
<li>Accutane Roche;</li>
<li>ALTI-Isotretinoin;</li>
<li>Clarus;</li>
<li>Epuris</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048091"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Acne Products</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Retinoic Acid Derivatives</span>;</li>
<li>
<span class="list-set-name">Retinoic Acid Derivative</span>;</li>
<li>
<span class="list-set-name">Vitamin A Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F185200"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The product formulation of Absorica LD (micronized) is not bioequivalent to other capsule formulations of isotretinoin (eg, Absorica, or softgel formulations: generics, Amnesteem, Claravis, Myorisan, Zenatane) and should not be substituted on a mg:mg basis.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="651bbdac-3bec-4b7d-afa0-73ebe0cb605e">Acne vulgaris, severe recalcitrant nodular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, severe recalcitrant nodular:</b> Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Softgel capsule (eg, generics, Amnesteem, Claravis, Myorisan, Zenatane) or hard-gelatin capsule (Absorica):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i> Oral: 0.5 mg/kg/day in 2 divided doses for 4 weeks, then increase dose to 1 mg/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-23637225'])">Ref</a></span>); for severe extensive cases (involving trunk, nuchal region, lower back, buttocks, thighs) may require higher doses up to 2 mg/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy:</i> Typically 15 to 20 weeks depending upon daily dose; a target cumulative dose range of 120 to 150 mg/kg has been recommended based on observed lower relapse rates with courses ≥120 mg/kg and the plateau effect observed with higher cumulative total doses of &gt;150 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Repeat course</i>: In older adolescents who have completed skeletal growth, a second course of isotretinoin may be repeated after a period of ≥2 months off therapy for persistent or recurring severe nodular acne; for younger patients who have not completed skeletal growth, the optimal interval before retreatment has not been defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Micronized hard-gelatin capsule (eg, Absorica LD): Oral: 0.4 to 0.8 mg/kg/day in 2 divided doses. In adults with severe, extensive cases (involving trunk, nuchal region, lower back, buttocks, thighs), higher doses up to 1.6 mg/kg/day in 2 divided doses have been used; pediatric data specific to the micronized dosage form is lacking. Duration of therapy is typically 15 to 20 weeks, until the total cyst count decreased by 70%, whichever is sooner. Based on experience with other isotretinoin dosage forms, in older adolescents who have completed skeletal growth, a second course of isotretinoin may be repeated after a period of ≥2 months off therapy for persistent or recurring severe nodular acne; for younger patients who have not completed skeletal growth, the optimal interval before retreatment has not been defined.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2a8b1434-d01f-4cbd-9f00-64c748b16194">Acne vulgaris, moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, moderate:</b> Limited data available: Children ≥12 years and Adolescents: Softgel capsule (eg, generics, Amnesteem, Claravis, Myorisan, Zenatane) and hard-gelatin capsule (Absorica): Oral: 0.25 to 0.4 mg/kg/day continued for 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-16546586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-16546586'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8cc2875-32c9-499e-8690-baebb3ee3f75">Neuroblastoma, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, maintenance:</b> Limited data available: Infants, Children, and Adolescents: Softgel capsule (eg, generics, Amnesteem, Claravis, Myorisan, Zenatane) and hard-gelatin capsule (Absorica): Oral: 80 mg/m<sup>2</sup>/dose every 12 hours for the last 2 weeks (14 consecutive days) of a 4-week cycle for 6 cycles; dinutuximab therapy is administered during the first week of the 4-week cycle (Yu 2010); begin after continuation chemotherapy or transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10519894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10519894'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128356"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51128357"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment</i>: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during treatment</i>: Mild liver enzymes may occur, and generally normalize with dosage reduction or with continued treatment; discontinue if normalization does not readily occur or if hepatitis (eg, transaminases &gt;3 times baseline) is suspected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18786498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18786498'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F185182"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8582" href="/d/html/8582.html" rel="external">see "Isotretinoin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Isotretinoin products are available in different formulations: a standard formulation (eg, Amnesteem, Claravis, Myorisan, Zenatane) that requires administration with food and lidose (Absorica) and micronized (Absorica LD) formulations that may be administered with or without food. Standard formulations are <b>not </b>bioequivalent to lidose or micronized formulations. Lidose and micronized formulations are <b>not</b> substitutable with one another due to differences in bioavailability.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> All dosing is based on use of a standard or lidose formulation unless otherwise indicated.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0a58f5c-8715-4ce0-9f16-c5cc0caba279">Acne vulgaris, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, moderate to severe: Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Standard or lidose formulation<b>: </b>0.5 mg/kg/day in 2 divided doses for 1 month, then increase to 1 mg/kg/day in 2 divided doses as tolerated; alternatively, may administer the total daily dose once daily to increase adherence to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Owen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Owen.1'])">Ref</a></span>). For patients with severe inflammatory acne (eg, acne conglobata) or deep comedonal acne, consider initial doses &lt;0.5 mg/kg/day (eg, 0.1 mg/kg/day) in combination with an oral glucocorticoid given before or at isotretinoin initiation and continued for the first 2 to 4 weeks of therapy to reduce the risk of severe acne flares (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-28619551','lexi-content-ref-Owen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-28619551','lexi-content-ref-Owen.1'])">Ref</a></span>). Continue until a total <b>cumulative</b> dose of 120 to 150 mg/kg is reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Micronized formulation: 0.4 to 0.8 mg/kg/day in 2 divided doses. Adults with very severe disease/scarring or primarily involving the trunk may require dosage adjustment up to 1.6 mg/kg/day in divided doses, as tolerated. Continue therapy until nodule count has been reduced by at least 70% or for up to 15 to 20 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternative low-dose regimen for moderate acne (off-label use)</i>: Standard or lidose formulation: 0.3 to 0.5 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-16546586','lexi-content-ref-21114478','lexi-content-ref-Owen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-16546586','lexi-content-ref-21114478','lexi-content-ref-Owen.1'])">Ref</a></span>). Continue until a total <b>cumulative</b> dose of 120 to 150 mg/kg is reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8035241d-374a-4148-bdb4-e510984c4460">Cutaneous T-cell lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous T-cell lymphomas (off-label use): Oral:</b> Induction: 1 mg/kg/day (in 2 divided doses and in combination with interferon alfa-2b) for 3 to 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12833006','lexi-content-ref-2007670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12833006','lexi-content-ref-2007670'])">Ref</a></span>). If response occurs, may continue therapy for an additional 3 months; if response continues after 6 months of therapy, may administer isotretinoin and interferon alfa-2b at a 50% reduced dose for an additional 3 months, followed by interferon alfa-2b maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2007670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2007670'])">Ref</a></span>). Additional trials may be necessary to further define the role of isotretinoin in the management of this condition.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a067b86f-2679-48c1-9934-6faf3a8a71ce">Squamous cell skin cancer, prevention in high-risk patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Squamous cell skin cancer, prevention in high-risk patients (off-label use): Oral:</b> Initial: 0.25 mg/kg every other day for 1 month, then 0.25 mg/kg daily for one month, then 0.5 mg/kg daily. Adjust dose as needed based on tolerance; higher doses may be more effective for severe skin cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16681667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16681667'])">Ref</a></span>). Additional data may be necessary to further define the role of isotretinoin in this setting.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990065"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987341"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment:</i> There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i> Liver enzymes may normalize with dosage reduction or with continued treatment; discontinue if normalization does not readily occur or if hepatitis is suspected.</p></div>
<div class="block arsc drugH1Div" id="F56423454"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone and growth effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Data are conflicting, but <b>decreased bone mineral density</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12437467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12437467'])">Ref</a></span>), <b>osteopenia</b>, <b>osteoporosis</b>, <b>bone fracture,</b> and delayed healing of bone fractures have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30858774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30858774'])">Ref</a></span>). Premature epiphyseal closure has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34626532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34626532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Possibly dose-related; related to pharmacologic action (ie, retinoids may lead to impaired bone growth) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9689293','lexi-content-ref-30858774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9689293','lexi-content-ref-30858774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; noted on imaging 6 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30858774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30858774'])">Ref</a></span>). Premature epiphyseal closure may occur months to years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34626532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34626532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses for prolonged durations may be associated with premature epiphyseal closure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34626532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34626532'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic predisposition for bone loss (eg, age-related osteoporosis, history of childhood osteoporosis conditions, osteomalacia, other disorders of bone metabolism)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of oral contraceptives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30858774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30858774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cutaneous/hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cutaneous adverse reactions associated with isotretinoin range from mucocutaneous effects such as <b>cheilitis</b>, <b>xeroderma</b>, <b>dry eye syndrome</b>, <b>conjunctivitis</b>, <b>blepharitis</b>, and episcleritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22508771','lexi-content-ref-28542914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22508771','lexi-content-ref-28542914'])">Ref</a></span>) to cases of <b>erythema nodosum</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32239897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32239897'])">Ref</a></span>), <b>pityriasis rosea</b>-like eruptions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28359163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28359163'])">Ref</a></span>), <b>pyogenic granuloma</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27885661','lexi-content-ref-12941114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27885661','lexi-content-ref-12941114'])">Ref</a></span>), <b>acne fulminans</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33423422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33423422'])">Ref</a></span>), <b>skin photosensitivity </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2145327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2145327'])">Ref</a></span>), and <b>pyoderma gangrenosum</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28624960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28624960'])">Ref</a></span>). Hypersensitivity reactions have also been reported, including immediate (<b>anaphylaxis</b>, <b>angioedema)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16405632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16405632'])">Ref</a></span>) and delayed reactions (<b>Stevens-Johnson syndrome </b>[SJS] (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28624960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28624960'])">Ref</a></span>), <b>toxic epidermal necrolysis</b>, <b>erythema multiforme-</b>like drug eruption, <b>acute generalized exanthematous pustulosis</b> [AGEP], allergic <b>vasculitis</b>, allergic myocardial infarction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31784393','lexi-content-ref-33987282','lexi-content-ref-20883276','lexi-content-ref-11816242','lexi-content-ref-28542914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31784393','lexi-content-ref-33987282','lexi-content-ref-20883276','lexi-content-ref-11816242','lexi-content-ref-28542914'])">Ref</a></span>). Inflammatory sacroiliitis has also been described with isotretinoin, in association with a HLA-B27 negative antigen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32034553','lexi-content-ref-32977793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32034553','lexi-content-ref-32977793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Immediate hypersensitivity reactions: Non–dose-related; immunologic (ie, IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30275849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Delayed hypersensitivity reactions: Non–dose-related, immunologic. SJS and AGEP are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>). Allergic myocardial infarction occurs due to mast cell degranulation following an allergic insult (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20828286']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20828286'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cheilitis: Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21198520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21198520'])">Ref</a></span>). Isotretinoin and its major metabolite, 4-oxo-isotretinoin, have been shown to have a phototoxic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2645585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2645585'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Immediate hypersensitivity reactions: Rapid; generally occurs within 1 hour of administration but may occur several hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.1','lexi-content-ref-16405632','lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.1','lexi-content-ref-16405632','lexi-content-ref-30275849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Delayed hypersensitivity reactions: Varied. Severe cutaneous adverse reactions, including SJS and AGEP, usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>). Allergic vasculitis usually occurs 6 weeks to 5 months after isotretinoin initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2570197']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2570197'])">Ref</a></span>) and has been reported to occur up to 6 weeks after discontinuation of isotretinoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2572922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2572922'])">Ref</a></span>). Allergic myocardial infarction can occur within 5 minutes of isotretinoin administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31784393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31784393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cutaneous reactions: Varied, with most reactions occurring 2 to 6 weeks after isotretinoin initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32239897','lexi-content-ref-28624960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32239897','lexi-content-ref-28624960'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Sacroiliitis: Delayed; occurs months to years after initiation of isotretinoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32034553','lexi-content-ref-32977793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32034553','lexi-content-ref-32977793'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clinical <b>hepatitis</b> and mild to moderate <b>increased liver enzymes</b> have been reported in ~15% of patients receiving isotretinoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25474452','lexi-content-ref-6238729','lexi-content-ref-22714752','lexi-content-ref-16924051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25474452','lexi-content-ref-6238729','lexi-content-ref-22714752','lexi-content-ref-16924051'])">Ref</a></span>). Reversibility back to baseline has been demonstrated within 4 weeks of discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6238729','lexi-content-ref-16924051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6238729','lexi-content-ref-16924051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; may be related to other comorbidities, concurrent drug therapy, or idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2039732','lexi-content-ref-16924051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2039732','lexi-content-ref-16924051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; occurring 1 to 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22714752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22714752'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent hepatotoxic medications, including alcohol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypertriglyceridemia and pancreatitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased serum triglycerides</b> occur in ~5% to 25% of patients receiving isotretinoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16924051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16924051'])">Ref</a></span>). Rare and potentially fatal <b>acute pancreatitis</b> may occur in patients with normal or elevated triglyceride levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32107726','lexi-content-ref-6238729','lexi-content-ref-27893168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32107726','lexi-content-ref-6238729','lexi-content-ref-27893168'])">Ref</a></span>). Case reports in adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29866513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29866513'])">Ref</a></span>) and adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27893168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27893168'])">Ref</a></span>) have demonstrated reversibility upon discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Retinoids increase apolipoproteins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22714752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22714752'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; seen within 2 weeks to 15 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11606952','lexi-content-ref-27893168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11606952','lexi-content-ref-27893168'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Elevated baseline triglycerides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32107726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32107726'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Weight &gt;89 kg males or &gt;73 kg females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11606952','lexi-content-ref-22714752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11606952','lexi-content-ref-22714752'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Musculoskeletal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Common and potentially fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22895802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22895802'])">Ref</a></span>) musculoskeletal symptoms (<b>arthralgia</b>, <b>myalgia</b>, <b>rhabdomyolysis</b>) have been reported in pediatric and adult patients; generally, symptoms were mild to moderate but occasionally required discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12786885','lexi-content-ref-32107726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12786885','lexi-content-ref-32107726'])">Ref</a></span>). Children may experience a higher frequency of myalgia, arthralgia, and back pain. Myalgia symptom resolution occurred with dose reduction, cessation of therapy, or treatment with a non-steroidal anti-inflammatory medication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32977793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32977793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; not clearly established. Hypothesized to cause cell membrane damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32977793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32977793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; onset can be 1 week to 3 months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12786885','lexi-content-ref-22895802','lexi-content-ref-32977793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12786885','lexi-content-ref-22895802','lexi-content-ref-32977793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High cumulative dose (&gt;1,800 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32977793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32977793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32977793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32977793'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Visual disturbance</b>, <b>night blindness</b>, <b>dry eye syndrome</b>, <b>eye irritation</b>, and <b>conjunctivitis </b>have been reported in 10% to 70% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32107726','lexi-content-ref-11606952','lexi-content-ref-25117163','lexi-content-ref-28542914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32107726','lexi-content-ref-11606952','lexi-content-ref-25117163','lexi-content-ref-28542914'])">Ref</a></span>). Cessation in therapy may reverse ocular effects; however, permanent damage may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25117163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25117163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Causes changes in the cornea, tear film composition, and visual process in the retina (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32683764','lexi-content-ref-25117163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32683764','lexi-content-ref-25117163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; seen after 3 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32683764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32683764'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11606952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11606952'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Weight &lt;70 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11606952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11606952'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypovitaminosis A (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25117163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25117163'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pseudotumor cerebri</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rare and reversible pseudotumor cerebri (<b>idiopathic intracranial hypertension</b>) has been documented in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30504951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30504951'])">Ref</a></span>) and in large scale adverse drug reporting systems (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15177980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15177980'])">Ref</a></span>). Symptoms are reversible with cessation of isotretinoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15177980','lexi-content-ref-15675888','lexi-content-ref-30504951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15177980','lexi-content-ref-15675888','lexi-content-ref-30504951'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30504951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30504951'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; onset is typically 2 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15177980','lexi-content-ref-30504951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15177980','lexi-content-ref-30504951'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use with tetracyclines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15177980','lexi-content-ref-15675888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15177980','lexi-content-ref-15675888'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">While data are conflicting, isotretinoin may cause <b>depression</b>,<b> psychosis</b>, mood disturbance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28542914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28542914'])">Ref</a></span>), and rarely, <b>suicidal ideation</b>, <b>suicidal tendencies</b>, death by suicide, <b>aggressive behavior</b>, and/or <b>violent behavior</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21903028','lexi-content-ref-32107726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21903028','lexi-content-ref-32107726'])">Ref</a></span>). Symptoms often resolve with therapy discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21903028','lexi-content-ref-28291553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21903028','lexi-content-ref-28291553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; the fat solubility of isotretinoin allows for passage through the blood brain barrier, possibly affecting the dopamine and serotonin or hypothalamic regulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21903028','lexi-content-ref-28291553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21903028','lexi-content-ref-28291553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; occurs between 1 to 4 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21903028','lexi-content-ref-28291553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21903028','lexi-content-ref-28291553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21903028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21903028'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying psychiatric diagnosis, in particular bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21903028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21903028'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F185146"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are for adults and adolescents unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (15%), increased serum triglycerides (25%; including cases reported &gt;800 mg/dL)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (15%, including increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤22%; severe arthralgia: adolescents: 2%), back pain (adolescents: 29%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density (adolescents: 9%)</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (transient), edema, flushing, palpitations, syncope, tachycardia, thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis, diaphoresis, eruptive xanthoma, erythema of skin, facial erythema, fragile skin, hair disease, hyperpigmentation, hypopigmentation, nail disease, paronychia, scaling of skin of feet, skin rash, sunburn, superficial peeling of palms</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Altered serum glucose, decreased libido, hirsutism, hyperuricemia, increased lactate dehydrogenase, increased LDL cholesterol, increased serum glucose, menstrual disease, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, decreased appetite, esophageal ulcer, esophagitis, gingival hemorrhage, gingivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction, gross hematuria, microscopic hematuria, proteinuria, pyuria, sexual disorder, vaginal dryness</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, bruise, decreased white blood cell count, increased erythrocyte sedimentation rate, lymphadenopathy, neutropenia, thrombocytopenia, thrombocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (disseminated), infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, asthenia, cerebrovascular accident, dizziness, drowsiness, emotional lability, euphoria, irritability, malaise, nervousness, outbursts of anger, pain, panic attack, paresthesia, psychosis, seizure, violent behavior, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, calcification of ligament, calcification of tendon, limb pain, myalgia, neck pain, skeletal hyperostosis, stiffness, tendinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Asthenopia, blepharitis, cataract, corneal opacity, decreased visual acuity, eye pruritus, hordeolum, increased lacrimation, keratitis, ocular hyperemia, optic neuritis, vision color changes</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Glomerulonephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, nasopharyngitis, respiratory tract infection, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Granulomatosis with polyangiitis (ten Holder 2002), vasculitis (ten Holder 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne fulminans (Fakih 2020), acute generalized exanthematous pustulosis (da Cunha Filho 2010), allergic skin reaction, alopecia (Vallerand 2018), cheilitis (Vallerand 2018), cheilosis (Vallerand 2018), dermatitis (Vallerand 2018), eczema (Vallerand 2018), erythema multiforme, erythema nodosum (Pasmatzi 2020), pityriasis rosea (Gürel 2018), pruritus (Vallerand 2018), pyoderma gangrenosum (Wang 2018), pyogenic granuloma (Simmons 2016), seborrhea (including seborrheic dermatitis) (Alharbi 2023), skin photosensitivity (Vallerand 2018), Stevens-Johnson syndrome (Vallerand 2018), toxic epidermal necrolysis, urticaria (Saray 2006), xeroderma (Vallerand 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (Opel 2017), colitis (including microscopic colitis) (Dukate 2022), diarrhea (Vallerand 2018), hemorrhagic pancreatitis, ileitis (Pereira-Nunes 2023), nausea (Vallerand 2018), vomiting (Vallerand 2018), xerostomia (Vallerand 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Ozdemir 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Kizilyel 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Bamidis 2021), angioedema (Saray 2006), hypersensitivity angiitis (Vallerand 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (Bremner 2012), auditory hallucinations (Vallerand 2018), depression (Vallerand 2018), fatigue (Vallerand 2018), headache (Vallerand 2018), insomnia (Vallerand 2018), intracranial hypertension (pseudotumor cerebri) (Tan 2019, Varoglu 2018), lethargy (Vallerand 2018), suicidal ideation (Bremner 2012), suicidal tendencies (Bremner 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Miziolek 2019), increased creatine phosphokinase in blood specimen (Marson 2022), musculoskeletal pain (Vallerand 2018), osteopenia (Miziolek 2019), osteoporosis (Miziolek 2019), premature epiphyseal closure (Alazawi 2011), rhabdomyolysis (Gutman-Yassky 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (Vallerand 2018), conjunctivitis (Vallerand 2018), dry eye syndrome (Vallerand 2018), eye irritation (Vallerand 2018), eyelid disease (meibomian gland dysfunction/atrophy) (Neudorfer 2012), night blindness (Teo 2014), photophobia (Vallerand 2018), visual disturbance (Vallerand 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment (Gainville 2021), tinnitus (Rosende 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry nose (Vallerand 2018), epistaxis (Vallerand 2018)</p></div>
<div class="block coi drugH1Div" id="F185160"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to isotretinoin or any component of the formulation; pregnancy. <b>Note: </b>Based on the chemical similarity of vitamin A to isotretinoin, the prescribing information of some products (eg, Absorica) lists sensitivity to vitamin A as a contraindication to isotretinoin therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications not in the US labeling: Breastfeeding, hepatic or renal insufficiency, hypervitaminosis A, excessive hyperlipidemia, concurrent tetracycline therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F185143"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Inflammatory bowel disease: Inflammatory bowel disease (IBD), including regional ileitis, has been reported in patients without a prior history of intestinal disorders; discontinue treatment immediately if abdominal pain, rectal bleeding, or severe diarrhea occurs. Of note, a position statement from the American Academy of Dermatology states that based on currently available data, there is insufficient evidence to prove either an association or a causal relationship between IBD and isotretinoin use (AAD 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Avoid prolonged exposure to UV rays or sunlight.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; impaired glucose control has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchange: Isotretinoin and tretinoin (which is also known as all-<i>trans</i> retinoic acid, or ATRA) may be confused, while both products may be used in cancer treatment, they are <b>not</b> interchangeable; verify product prior to dispensing and administration to prevent medication errors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some products may contain tartrazine (FD&amp;C yellow no. 5), which may cause allergic reactions, including bronchial asthma, in certain individuals. Allergy is frequently seen in patients who also have an aspirin hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood donation: Patients should be instructed not to donate blood during therapy and for 1 month following discontinuation of therapy due to risk of donated blood being given to a pregnant patient.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced health care provider: This medication should only be prescribed by health care providers competent in treating severe recalcitrant nodular acne and experienced with the use of systemic retinoids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Long-term use: Safety of long-term use is not established and is not recommended; the effect on bone loss is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin resurfacing procedures: Avoid skin resurfacing procedures (eg, dermabrasion, laser) and wax epilation during therapy and for ≥6 months after discontinuation of isotretinoin due to the risk of scarring.</p></div>
<div class="block foc drugH1Div" id="F185155"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica: 10 mg, 20 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica: 25 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #5 (tartrazine), fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica: 30 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica: 35 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica: 40 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica LD: 8 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica LD: 16 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica LD: 24 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica LD: 32 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane: 10 mg [DSC] [contains edetate (edta) disodium, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigotine,indigo carmine), methylparaben, propylparaben, quinoline (d&amp;c yellow #10) aluminum lake, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane: 10 mg [contains edetate (edta) disodium, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), methylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane: 20 mg [DSC] [contains disodium edta, fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40(allura red ac)aluminum lake, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane: 20 mg [contains edetate (edta) disodium, fd&amp;c blue #2 (indigotine,indigo carmine), methylparaben, propylparaben, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane: 30 mg [contains disodium edta, fd&amp;c blue #2 (indigotine,indigo carmine), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane: 30 mg [contains edetate (edta) disodium, fd&amp;c blue #2 (indigo carm) aluminum lake, methylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane: 40 mg [DSC] [contains disodium edta, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigotine,indigo carmine), quinoline (d&amp;c yellow #10) aluminum lake, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane: 40 mg [contains edetate (edta) disodium, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), methylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amnesteem: 10 mg, 20 mg, 40 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claravis: 10 mg [contains fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claravis: 20 mg, 30 mg [contains edetate (edta) disodium, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claravis: 40 mg [contains edetate (edta) disodium, fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myorisan: 10 mg [DSC], 20 mg [DSC] [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myorisan: 30 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myorisan: 40 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zenatane: 10 mg [contains edetate (edta) disodium, fd&amp;c blue #1 (brilliant blue), methylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zenatane: 20 mg [contains edetate (edta) disodium, methylparaben, propylparaben, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zenatane: 30 mg [contains edetate (edta) disodium, fd&amp;c blue #2 (indigo carm) aluminum lake, methylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zenatane: 40 mg [contains edetate (edta) disodium, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), methylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg</p></div>
<div class="block geq drugH1Div" id="F185139"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323242"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Absorica LD Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $49.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 mg (per each): $49.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">24 mg (per each): $52.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">32 mg (per each): $52.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Absorica Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $44.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $44.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $48.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $48.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $48.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $48.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Accutane Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $7.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $7.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $7.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $7.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Amnesteem Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $18.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $21.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $24.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Claravis Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $20.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $24.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $20.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $28.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (ISOtretinoin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $7.19 - $42.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $7.19 - $42.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $36.61 - $45.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $7.19 - $45.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $36.61 - $45.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $7.19 - $45.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Zenatane Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $18.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $21.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $24.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $24.83</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867284"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica LD: 8 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica LD: 16 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica LD: 24 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Absorica LD: 32 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane Roche: 10 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Accutane Roche: 40 mg [contains fd&amp;c yellow #6 (sunset yellow), methylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clarus: 10 mg, 40 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epuris: 10 mg, 20 mg, 30 mg, 40 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 40 mg</p></div>
<div class="block exp drugH1Div" id="F5935063"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">For patients unable to swallow the capsules whole, an oral liquid may be prepared with softgel capsules (not recommended by the manufacturers) by one of the following methods:</p>
<p style="text-indent:-2em;margin-left:4em;">Place capsules (softgel formulations only) in small container and add warm (~37°C [97°F]) water or milk to cover capsule(s); wait 2 to 3 minutes until capsule is softened and then drink the milk or water with the softened capsule, or swallow softened capsule.</p>
<p style="text-indent:-2em;margin-left:4em;">Puncture capsule (softgel formulations only) with needle or cut with scissors; squeeze capsule contents into 5 to 10 mL of milk or tube feed formula; draw mixture up into oral syringe and administer via feeding tube; flush feeding tube with ≥30 mL additional milk or tube feeding formula.</p>
<p style="text-indent:-2em;margin-left:4em;">Puncture capsule (softgel formulations only) with needle or cut with scissors and draw contents into oral syringe; add 1 to 5 mL of medium chain triglyceride, soybean, or safflower oil to the oral syringe; mix gently and administer via feeding tube; flush feeding tube with ≥30 mL milk or tube feeding formula.</p>
<div class="reference">Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy.</i> 2011;31(2):164-192.<span class="pubmed-id">21275495</span></div>
</div>
<div class="block admp drugH1Div" id="F52613099"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Softgel (eg, generics, Amnesteem, Claravis, Myorisan, Zenatane): Administer orally with a meal. According to the manufacturers’ labeling, capsules should be swallowed whole with a full glass of liquid. For patients unable to swallow capsule whole, an oral liquid may be prepared (see Extemporaneous Preparations). Contents removed from capsules may irritate esophagus.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neuroblastoma:</i> In pediatric neuroblastoma trials when patient was unable to swallow capsule, the end of capsule was punctured/cut and capsule's contents extruded into ice cream or yogurt (high-fat food); if capsule is opened, contents must be consumed immediately to avoid degradation of the drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10519894','lexi-content-ref-17224928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10519894','lexi-content-ref-17224928'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Hard-gelatin capsules (Absorica, Absorica LD [micronized]): May be taken without regard to meals.</p></div>
<div class="block adm drugH1Div" id="F185157"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer standard formulation with a meal; lidose (Absorica) or micronized (Absorica LD) formulations may be taken without regard to meals. According to the manufacturer's labeling, capsules should be swallowed whole with a full glass of liquid; do not chew or suck on the capsule. For patients unable to swallow capsule whole, an oral liquid may be prepared (see "Extemporaneously Prepared"); may irritate esophagus if contents are removed from the capsule. Safety of once-daily dosing of isotretinoin has not been established and is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Neuroblastoma (off-label use): In a pharmacokinetic study, the end of the capsule was punctured/cut and capsule contents extruded into ice cream or yogurt if patients were unable to swallow capsules whole; if capsule is opened, contents must be consumed immediately to avoid degradation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17224928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17224928'])">Ref</a></span>). Refer to "Extemporaneously Prepared" for additional information.</p></div>
<div class="block hazard drugH1Div" id="F49132640"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Isotretinoin may cause teratogenicity and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F185172"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77° F); excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block meg drugH1Div" id="F7874644"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Absorica: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F021951s013lbl.pdf%23page%3D32&amp;token=VHzLq543b73LoIx4jtGVGJEEg3rSOdXEsNwHRA%2FuvUcFUEEI1xW8lJrmP93JcvbSdoltIM9SYRRrsvvK04hMLHXmls%2BTg1pFX7lc9nDOk9aEWHlrj1PPaBEt7hNZpGpP&amp;TOPIC_ID=13395" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021951s013lbl.pdf#page=32</a></p>
<p style="text-indent:-2em;margin-left:4em;">Accutane: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2010%2F018662s061MedGuide.pdf&amp;token=L42bcm227jlyd0MLHrvc3Mbqpb%2BC7PzA7csKNlLpIPbqh0gQ%2BKaaVou1J4UZMbjM7LnNtXzdl44sp5xqb%2FzjGANMEVMlYvMMGOQHgXRm3m4SW0eEPm5sDa1%2F59zMkC4I&amp;TOPIC_ID=13395" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018662s061MedGuide.pdf</a></p>
<p style="text-indent:-2em;margin-left:4em;">Sotret: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2FSotret.pdf&amp;token=fVgQTmAZ%2BmzTTN6p%2F%2FY27eZ1%2ByLzSFk580n%2BbZxueZ5XHvTZMmokkkdmw5nlzcnRLp7y89rIkXkGTswbjQaqFamiwtJq62hF7nMCkc%2FBUcY%3D&amp;TOPIC_ID=13395" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/Sotret.pdf</a></p></div>
<div class="block usep drugH1Div" id="F53567419"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of severe recalcitrant nodular acne unresponsive to conventional therapy, including systemic antibiotics (FDA approved in ages ≥12 years and adults); has also been used for the treatment of moderate acne and high-risk neuroblastoma.</p></div>
<div class="block mst drugH1Div" id="F185227"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Accutane may be confused with Accolate, Accupril.</p>
<p style="text-indent:-2em;margin-left:4em;">Claravis may be confused with Cleviprex.</p>
<p style="text-indent:-2em;margin-left:4em;">ISOtretinoin may be confused with tretinoin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Isotretinoin may be confused with tretinoin (which is also called all-<i>trans</i> retinoic acid, or ATRA); while both products may have uses in cancer treatment, they are <b>not</b> interchangeable.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299550"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F185148"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of ISOtretinoin (Systemic). Specifically, the risk for elevated triglyceride concentrations may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Retinoic Acid Derivatives may enhance the hepatotoxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: ISOtretinoin (Systemic) may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Progestins (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives. Microdosed progesterone-only preparations (ie, minipills that do not contain estrogen) are considered an inadequate method of contraception.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valoctocogene Roxaparvovec: ISOtretinoin (Systemic) may diminish the therapeutic effect of Valoctocogene Roxaparvovec. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin A: May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F185173"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Standard formulation isotretinoin bioavailability increased if taken with food or milk. Management: Administer orally with a meal. <b>Note:</b> Also available as lidose (Absorica) and micronized (Absorica LD) formulations that may be administered with or without food.</p></div>
<div class="block dic drugH1Div" id="F185164"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Standard formulation should be taken with food; lidose (Absorica) or micronized formulations (Absorica LD) may be taken without regard to meals. Limit intake of vitamin A; avoid use of other vitamin A products. Some formulations may contain soybean oil.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307966"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: Isotretinoin must not be used by patients who may become pregnant.</b></p>
<p style="text-indent:0em;margin-top:2em;">Patients of childbearing potential must be able to comply with the guidelines of the iPLEDGE™ pregnancy prevention program. Females of childbearing potential must have 2 negative pregnancy tests with a sensitivity of ≥25 milliunits/mL prior to beginning therapy, and testing should continue monthly during therapy. Patients of childbearing potential should not become pregnant during therapy or for 1 month following discontinuation of isotretinoin. Upon discontinuation of treatment, patients of childbearing potential should have a pregnancy test after their last dose and again 1 month after their last dose.</p>
<p style="text-indent:0em;margin-top:2em;">All patients (male and female) must be enrolled in the iPLEDGE™ risk management program. Patients of childbearing potential must receive oral and written information reviewing the hazards of therapy and the effects that isotretinoin can have on a fetus. Therapy should not begin without 2 negative pregnancy tests ≥19 days apart. Two forms of contraception (a primary and secondary form as described in the iPLEDGE™ program materials) must be used simultaneously beginning 1 month prior to treatment, during treatment, and for 1 month after therapy is discontinued; limitations to their use must be explained. Micro-dosed progesterone products that do not contain an estrogen ("mini-pills") are not an acceptable form of contraception during isotretinoin treatment. Prescriptions should be written for no more than a 30-day supply, and pregnancy testing and counseling should be repeated monthly. During therapy, pregnancy tests must be conducted by a CLIA-certified laboratory. Prescriptions must be filled and picked up from the pharmacy within 7 days of specimen collection for pregnancy test for patients of childbearing potential. Prescriptions for patients of nonchildbearing potential (male and female) must be filled and picked up within 30 days of prescribing.</p>
<p style="text-indent:0em;margin-top:2em;">Any cases of accidental pregnancy should be reported to the iPLEDGE™ program or FDA MedWatch. All patients (male and female) must read and sign the informed consent material provided in the pregnancy prevention program.</p></div>
<div class="block pri drugH1Div" id="F185163"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Isotretinoin and its metabolites can be detected in fetal tissue following maternal use during pregnancy (Benifla 1995; Kraft 1989).</p>
<p style="text-indent:0em;margin-top:2em;">Use is contraindicated in pregnant women.<b> [US Boxed Warning]: Isotretinoin must not be used by patients who are pregnant. There is an extremely high risk that life-threatening birth defects can result if pregnancy occurs while taking isotretinoin in any amount, even for short periods of time. Potentially, any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. Birth defects that have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, CNS, cardiovascular system, and thymus and parathyroid glands. Cases of intelligence quotient (IQ) scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported. Documented external abnormalities include skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities include CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases, death has occurred with some of the abnormalities previously noted.</b></p>
<p style="text-indent:0em;margin-top:2em;">If pregnancy does occur during treatment of a patient who is taking isotretinoin, isotretinoin must be discontinued immediately and the patient should be referred to an obstetrician-gynecologist experienced in reproductive toxicity for further evaluation and counseling.</p>
<p style="text-indent:0em;margin-top:2em;">Any pregnancies should be reported to the iPLEDGE™ program (www.ipledgeprogram.com or 866-495-0654) and the FDA through MedWatch (800-FDA-1088).</p></div>
<div class="block mopp drugH1Div" id="F53567418"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count, baseline sedimentation rate, glucose, CPK; signs of depression, mood alteration, psychosis, aggression, severe skin reactions</p>
<p style="text-indent:-2em;margin-left:2em;">Pregnancy test (for all female patients of childbearing potential): Two negative tests with a sensitivity of at least 25 mIU/mL prior to beginning therapy (the second performed at least 19 days after the first test and performed during the first 5 days of the menstrual period immediately preceding the start of therapy); monthly tests to rule out pregnancy prior to refilling prescription</p>
<p style="text-indent:-2em;margin-left:2em;">Lipids: Prior to treatment and at weekly or biweekly intervals until response to treatment is established. Test should not be performed &lt;36 hours after consumption of ethanol.</p>
<p style="text-indent:-2em;margin-left:2em;">Liver function tests: Prior to treatment and at weekly or biweekly intervals until response to treatment is established.</p></div>
<div class="block pha drugH1Div" id="F185142"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reduces sebaceous gland size and reduces sebum production in acne treatment; in neuroblastoma, decreases cell proliferation and induces differentiation</p></div>
<div class="block phk drugH1Div" id="F185159"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Pharmacokinetic parameters in adolescents (12 to 15 years) are similar to adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Standard formulation: Enhanced with a high-fat meal.</p>
<p style="text-indent:-2em;margin-left:4em;">Lidose formulation (Absorica): AUC<sub>0-t </sub>and C<sub>max</sub> increased 50% and 26%, respectively, under fed compared to fasting conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">Micronized formulation (Absorica LD): AUC<sub>0-t </sub>and C<sub>max</sub> increased 20% and 6%, respectively, under fed compared to fasting conditions.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99% to 100%; primarily albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2B6, 2C8, 2C9, 3A4; forms metabolites; major metabolite: 4-oxo-isotretinoin (active).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Standard formulation: Parent drug: 21 ± 8.2 hours; Metabolite: 24 ± 5.3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Lidose formulation (Absorica): Parent drug: 18 hours; Metabolite: 38 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Micronized formulation (Absorica LD): Parent drug: ~24 hours; Metabolite: ~38 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Standard formulation: 5.3 hours (fed); 3.2 hours (fasting).</p>
<p style="text-indent:-2em;margin-left:4em;">Lidose formulation (Absorica): 6.4 hours (fed); 2.9 hours (fasting).</p>
<p style="text-indent:-2em;margin-left:4em;">Micronized formulation (Absorica LD): Median: 5 hours (fed); 3.5 hours (fasting).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces (equal amounts).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F185165"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Curacne | Decutan | Isosupra Lidose | Oratane | Reducar | Roaccutane | Ruatine | Sotret | Tretin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">A-cnotren | Curacne | Flexresan | Isocutan | Isotan | Retinide | Roaccutan | Scheritonin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ciscutan | Isotretinoin hexal pharma | Isotretinoin pelpharma | Isotretinoin ratiopharm | Lurantal | Roaccutan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Accure | Apo isotretinoin | Cm isotretinoin | Dermatane | Isohexal | Isotretinoin an | Isotretinoin gx | Isotretinoin lupin | Isotretinoin pfizer | Isotretinoin scp | Isotretinoin-bc | Oratane | Roaccutane | Rocta | Tw isotretinoin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Reticap | Roaccutane</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Isocural | Isotretinoin bailleul | Isotretinoine | Isotretinoine ratiopharm | Isotretinoine sandoz | Roaccutane</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Roaccutan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acnil | Acnova | Amalfi | Cecnoin | Isoacne | Isoface | Ison | Isotrat | Isotretinoina | Lurantal | Roacutan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Isoroc | Isotretinoin mepha | Isotretinoin sandoz | Isotretinoin teva | Roaccutan | Roaccutane | Tretinac</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acneral | Acnotin | Hyndriax | Isdiben | Lisacne | Oralne | Piplex | Roacnetan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Roaccutane | Tai er si</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acnotin | Atretin | Dermalona | Hyndriax | Isoface | Isotretinoina | Lurantal | Proacnetin | Reytrin | Roaccutan | Rovacor | Sotret | Tretinex | Tretinova</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aknenormin | Curacne | Isotretinoin belupo | Roaccutan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aknefug iso | Aknenormin | Isoderm | Isogalen | Isopel | Isotiorga | Isotret | Isotretinoin actavis | Isotretinoin basics | Isotretinoin Isis | Isotretinoin puren | Isotretinoin ratiopharm | Isotretinoin stada | Meditretin | Roaccutan | Roaccutane</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Isotretinoin alpharma | Isotretinoin ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Isoface | Isolve | Piplex | Roaccutane | Rocut | Xaltax</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cuticlin | Hyndriax | Isoface | Isotretinoina | Lisacne | Neutin | Piplex | Retiacne | Roaccutane | Tretinex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Isotretinoin sandoz | Roaccutane</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acnelofix | Iso acnetin | Netlook | Roaccutane | Roaccutrex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acnemin | Dercutane | Farmacne | Flexresan | Isdiben | Isoacne | Isotretinoina | Isotretinoina sun | Mayesta | Roacutan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Isotretinoin alpha | Isotretinoin Alternova | Isotretinoin orifarm | Isotretinoin orion | Isotretinoin ratio | Isotretinoin sandoz | Isotretinoin sanoswiss | Roaccutan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acnetrait | Curacne | Isotretinoine Dci | Procuta | Roaccutane</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Isotretinoin Kent | Isotretinoin medreich | Roaccutane</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">A-cnotren | Accuran | Acnogen | Curacne | Reducar | Roaccutan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Acnotin | Nimegen | Oratane | Roaccutane</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Roaccutane</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aknenormin | Inerta | Isotretinoin bailleul | Isotretinoin ratiopharm | Medinac | Roaccutan | Sotret | Sotret neo</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Roaccutane</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Curatane | Roaccutane</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acnestar | Acnex | Acnezac | Acno | Actame | Acutret | Aknea | D'acne i | Deriva i | Ethitret | Eunozit | Finetret | I 10 | I lax | I top | Ibitret | Iret | Irosis | Isac | Iso aret | Isobest | Isobrill | Isoderma | Isoin | Isokon | Isonak | Isopex | Isotane | Isotroin | Lacne | Nayzit | Nutret | Ocotret | Oraret | Pinoin | Regiso | Resoten | Rezisort | Saferet | Skinista | Sotret | Sotret nf | Sysret | Tetilin | Tretin iso | Tretiva | Tufacne | Tyret o | Zidoin | Zinderm iso | Zit | Zitblow | Zitvin iso</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Decutan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aisoskin | Isdiben | Isodifa | Isoriac | Isotretinoina difa cooper | Isotretinoina eg | Isotretinoina sun | Roaccutan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Curacne | Isosupra Lidose | Roaccutane | Ruatine | Xeractan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Isotrex | Isotrin | Isotroin | Oratane | Roaccutane</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Accunetan | Acnal | Acnon | Acrein | Akinol | Aknal | Clare | Detha | Isopact | Isotam | Isotina | Isotinon | Isotren | Lecibum | Leseabeum | Loac | Lostan | Mycutane | Newtinon | Nimegen | Opiqutan | Pinple | Roaccutane | Roitan | Trein | Trenon | Tretin | Wooriccutane | Zerocutan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Curacne | Decutan | Roaccutane | Ruatine | Xeractan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">A-cnotren | Acnogen | Contracne | Curacne | Flexresan | Humatret | Isotroin | Orotrex | Roaccutane | Sotret</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Isotretinoin sandoz | Roaccutan | Roaccutane</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Curacne | Isotretinoin bailleul | Isotretinoine eg | Roaccutane</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Roaccutan | Roaccutane</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acno | Curacne | Orotrex | Roaccutane | Sotret | Tretacne | Xeractan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Diacarin | Faclynel | Gelcupro | Isoface | Neotrex | Oratane | Roaccutan | Trevissage | Vastionin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Oratane | Roaccutane</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Curacne | Isotretinoine | Isotretinoine sandoz | Isotretinoine sun | Roaccutan | Roaccutane</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Isotretinoin orifarm | Roaccutan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Isotane | Oratane | Roaccutane</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dicutan | Dyradin | Hyndriax | Isdiben | Isocheck | Isocler | Isoface | Lisacne | Piplex | Roaccutan | Tetroin a | Tretocheck</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acnoin | Acutrex | Isonoin | Roaccutane | Treviso</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acnex | Acnoz | Arynoin | Atractin | Daxar | Freac | Iret | Isoderm | Isofit | Isolex | Isonas | Isotop | Isozam | Maxinoin | Myso | Novsont | Oratane | Roaccutane | Saitrin | Serbica | Sonion | Soretin | Tecklex | Tretigen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Actaven | Aknenormin | Axotret | Curacne | Isoderm | Izotek | Procuta | Roaccutan | Tretinex | Tretoskin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Absorica | Absorica ld | Accutane | Amnesteem | Claravis | Myorisan | Sotret | Zenatane</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Isoprotil | Isotretinoina | Isotretinoina pierre fabre | Orotrex | Roaccutan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acnecur | Isotretinoina dutriec | Piplex | Roaccutan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Curacne | Reducar | Roaccutane | Ruatine | Sotret | Xeractan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acnecutan | Roaccutan | Roaccutane | Sotret | Verocutan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Oratane | Roaccutane | Ruatine | Xeractan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Isotracin | Isotretinoin actavis | Isotretinoin bijon | Isotretinoin orifarm | Isotretinoin paranova | Isotretinoin sandoz</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Nimegen | Oratane | Roaccutane</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Retitren | Roaccutan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aknenormin | Beloretin | Curacne | Isotretinoin actavis | Roaccutan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Acnetrex | Acnotin | Isotane | Proacne | Roaccutane | Roacta | Sotret</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Acneta | Curacne | Curacne ge | Roaccutane</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Acnegen | Aknetrent | Roaccutane | Zoretanin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Roaccutane</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acnetin | Roaccutan</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Acnotin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Isotroin | Roaccutan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cuticlin | Isoface | Isotretinoina | Oratane | Roaccutan</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Acmolrine | Solondo | Tilbec | Vistrinin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acnetane | Apex-isotretinion | Oratane | Roaccutane</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Absorica.1">
<a name="Absorica.1"></a>Absorica/Absorica LD (isotretinoin) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Absorica.1">
<a name="Absorica.1"></a>Absorica/Absorica LD (isotretinoin) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Accutane.1">
<a name="Accutane.1"></a>Accutane (isotretinoin) [prescribing information]. Scottsdale, AZ: JG Pharma, Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Accutane.2">
<a name="Accutane.2"></a>Accutane Roche (isotretinoin) [prescribing information]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31784393">
<a name="31784393"></a>Alataş ÖD, Alataş ET. Isotretinoin-induced pruritic erythematous lesions and acute chest pain in a 15-year-old girl. <i>Am J Emerg Med</i>. 2020;38(5):1043.e1-1043.e3. doi:10.1016/j.ajem.2019.158479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/31784393/pubmed" id="31784393" target="_blank">31784393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34626532">
<a name="34626532"></a>Alazawi S, Hendriksz T. Analysis of the effects of isotretinoin on the premature epiphyseal closure in pediatric populations: a literature review. <i>J Osteopath Med</i>. 2021. doi: 10.1515/jom-2021-0108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/34626532/pubmed" id="34626532" target="_blank">34626532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37288194">
<a name="37288194"></a>Alharbi A, Aljehani FH, Siddique A, Alosaimi AK, Assiri S. Seborrheic dermatitis-like eruption induced by isotretinoin: a case report. <i>Cureus</i>. 2023;15(5):e38665. doi:10.7759/cureus.38665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/37288194/pubmed" id="37288194" target="_blank">37288194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAD.1">
<a name="AAD.1"></a>American Academy of Dermatology website. Position statement on isotretinoin. https://www.aad.org/Forms/Policies/Uploads/PS/PS-Isotretinoin.pdf. Accessed August 1, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16546586">
<a name="16546586"></a>Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. <i>J Am Acad Dermatol</i>. 2006;54(4):644-646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/16546586/pubmed" id="16546586" target="_blank">16546586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31784393">
<a name="31784393"></a>Amnesteem (isotretinoin) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; August 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/31784393/pubmed" id="31784393" target="_blank">31784393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33987282">
<a name="33987282"></a>Annangi S, Pasha S. Isotretinoin induced small vessel vasculitis: a life-threatening pulmonary-renal syndrome-a case report. <i>Ann Transl Med</i>. 2021 Apr;9(7):584. doi:10.21037/atm-20-4212. Erratum in: <i>Ann Transl Med</i>. 2021;9(14):1217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/33987282/pubmed" id="33987282" target="_blank">33987282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2145327">
<a name="2145327"></a>Auffret N, Bruley C, Brunetiere RA, Decot MC, Binet O. Photoaggravated allergic reaction to isotretinoin. <i>J Am Acad Dermatol</i>. 1990;23(2 Pt 1):321-322. doi:10.1016/s0190-9622(08)81245-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2145327/pubmed" id="2145327" target="_blank">2145327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34627369">
<a name="34627369"></a>Bamidis A, Hofmann SC. Isotretinoin-associated exercise-induced anaphylaxis in a patient with birch pollinosis and soybean sensitization: case presentation and literature review. <i>Allergy Asthma Clin Immunol</i>. 2021;17(1):101. doi:10.1186/s13223-021-00604-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/34627369/pubmed" id="34627369" target="_blank">34627369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7639942">
<a name="7639942"></a>Benifla JL, Ville Y, Imbert MC, et al. Fetal tissue dosages of retinoids. Experimental study concerning a case of isotretinoin (Roaccutan) administration and pregnancy. Fetal Diagn Ther. 199510(3):189-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/7639942/pubmed" id="7639942" target="_blank">7639942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20828286">
<a name="20828286"></a>Biteker M. Current understanding of Kounis syndrome. <i>Expert Rev Clin Immunol</i>. 2010;6(5):777-788. doi:10.1586/eci.10.47<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/20828286/pubmed" id="20828286" target="_blank">20828286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12894062">
<a name="12894062"></a>Brecher AR and Orlow SJ, "Oral Retinoid Therapy for Dermatologic Conditions in Children and Adolescents," <i>J Am Acad Dermatol</i>, 2003, 49(2):171-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/12894062/pubmed" id="12894062" target="_blank">12894062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18786498">
<a name="18786498"></a>Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. <i>Semin Cutan Med Surg</i>. 2008;27(3):197‐206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/18786498/pubmed" id="18786498" target="_blank">18786498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21903028">
<a name="21903028"></a>Bremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. <i>J Clin Psychiatry</i>. 2012;73(1):37-50. doi:10.4088/JCP.10r05993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/21903028/pubmed" id="21903028" target="_blank">21903028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Claravis.1">
<a name="Claravis.1"></a>Claravis (isotretinoin) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Claravis.1">
<a name="Claravis.1"></a>Claravis (isotretinoin) [prescribing information]. Etobicoke, Ontario, Canada: Mylan Pharmaceuticals ULC; January 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clarus.1">
<a name="Clarus.1"></a>Clarus (isotretinoin) [prescribing information]. Etobicoke, Ontario, Canada: Mylan Pharmaceuticals ULC; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20883276">
<a name="20883276"></a>da Cunha Filho RR, de Almeida HL Jr, Lorencette NA, Fillus Netto J. Acute generalized exanthematous pustulosis induced by isotretinoin. <i>Int J Dermatol</i>. 2010;49(9):1077-1079. doi:10.1111/j.1365-4632.2009.04327.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/20883276/pubmed" id="20883276" target="_blank">20883276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6238291">
<a name="6238291"></a>DiGiovanna JJ and Peck GL, “Oral Synthetic Retinoid Treatment in Children,” <i>Pediatr Dermatol</i>, 1983, 1(1):77-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/6238291/pubmed" id="6238291" target="_blank">6238291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36072354">
<a name="36072354"></a>Dukate LR, Pak K, O'Connell W, Junga Z. A small blemish: isotretinoin-induced microscopic colitis. <i>ACG Case Rep J</i>. 2022;9(9):e00838. doi:10.14309/crj.0000000000000838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/36072354/pubmed" id="36072354" target="_blank">36072354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12833006">
<a name="12833006"></a>Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. <i>J Am Acad Dermatol</i>. 2003;49(1):35-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/12833006/pubmed" id="12833006" target="_blank">12833006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2570197">
<a name="2570197"></a>Dwyer JM, Kenicer K, Thompson BT, et al. Vasculitis and retinoids. <i>Lancet</i>. 1989;2(8661):494-496. doi:10.1016/s0140-6736(89)92099-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2570197/pubmed" id="2570197" target="_blank">2570197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23637225">
<a name="23637225"></a>Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics</i>. 2013;131(Suppl 3):S163-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/23637225/pubmed" id="23637225" target="_blank">23637225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32034553">
<a name="32034553"></a>Elnady B, Elkhouly T, Dawoud NM, et al. New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. <i>Clin Rheumatol</i>. 2020;39(6):1829-1838. doi:10.1007/s10067-020-04957-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/32034553/pubmed" id="32034553" target="_blank">32034553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epuris.2020.08">
<a name="Epuris.2020.08"></a>Epuris (isotretinoin) [product monograph]. Oakville, Ontario, Canada: Cipher Pharmaceuticals Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33423422">
<a name="33423422"></a>Fakih A, Goens J, Grozdev I, Dangoisse C, Richert B. Acne fulminans induced by a low dose isotretinoin: case report and review of the literature. <i>Dermatol Online J</i>. 2020;26(12):13030/qt14h2419w.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/33423422/pubmed" id="33423422" target="_blank">33423422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645585">
<a name="2645585"></a>Ferguson J, Johnson BE. Retinoid associated phototoxicity and photosensitivity. <i>Pharmacol Ther</i>. 1989;40(1):123-135. doi:10.1016/0163-7258(89)90079-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2645585/pubmed" id="2645585" target="_blank">2645585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15177980">
<a name="15177980"></a>Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. <i>Ophthalmology</i>. 2004;111(6):1248-1250. doi:10.1016/j.ophtha.2003.09.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/15177980/pubmed" id="15177980" target="_blank">15177980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15675888">
<a name="15675888"></a>Friedman DI. Medication-induced intracranial hypertension in dermatology. <i>Am J Clin Dermatol</i>. 2005;6(1):29-37. doi:10.2165/00128071-200506010-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/15675888/pubmed" id="15675888" target="_blank">15675888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33200354">
<a name="33200354"></a>Gainville A, Rousseau V, Kaguelidou F, et al. Drug-induced hearing loss in children: an analysis of spontaneous reports in the French PharmacoVigilance Database. <i>Paediatr Drugs</i>. 2021;23(1):87-93. doi:10.1007/s40272-020-00425-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/33200354/pubmed" id="33200354" target="_blank">33200354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28619551">
<a name="28619551"></a>Greywal T, Zaenglein AL, Baldwin HE, et al. Evidence-based recommendations for the management of acne fulminans and its variants. <i>J Am Acad Dermatol</i>. 2017;77(1):109-117. doi:10.1016/j.jaad.2016.11.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/28619551/pubmed" id="28619551" target="_blank">28619551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28359163">
<a name="28359163"></a>Gürel G, Şahin S, Çölgeçen E. Pityriasis rosea-like eruption induced by isotretinoin. <i>Cutan Ocul Toxicol</i>. 2018;37(1):100-102. doi:10.1080/15569527.2017.1312430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/28359163/pubmed" id="28359163" target="_blank">28359163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12786885">
<a name="12786885"></a>Guttman-Yassky E, Hayek T, Muchnik L, Bergman R. Acute rhabdomyolysis and myoglobinuria associated with isotretinoin treatment. <i>Int J Dermatol</i>. 2003;42(6):499-500. doi:10.1046/j.1365-4362.2003.01917.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/12786885/pubmed" id="12786885" target="_blank">12786885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22895802">
<a name="22895802"></a>Hartung B, Merk HF, Huckenbeck W, Daldrup T, Neuen-Jacob E, Ritz-Timme S. Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin. <i>Int J Legal Med</i>. 2012;126(6):953-956. doi:10.1007/s00414-012-0750-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/22895802/pubmed" id="22895802" target="_blank">22895802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15116059">
<a name="15116059"></a>Hendrix CW, Jackson KA, Whitmore E, et al, “The Effect of Isotretinoin on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Norethindrone,” <i>Clin Pharmacol Ther</i>, 2004, 75(5):464-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/15116059/pubmed" id="15116059" target="_blank">15116059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28291553">
<a name="28291553"></a>Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. <i>J Am Acad Dermatol</i>. 2017;76(6):1068-1076.e9. doi: 10.1016/j.jaad.2016.12.028. Erratum in: <i>J Am Acad Dermatol</i>. 2017 Nov 14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/28291553/pubmed" id="28291553" target="_blank">28291553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32977793">
<a name="32977793"></a>Karaosmanoğlu N, Mülkoğlu C. Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study. <i>BMC Musculoskelet Disord</i>. 2020;21(1):631. doi:10.1186/s12891-020-03656-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/32977793/pubmed" id="32977793" target="_blank">32977793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9689293">
<a name="9689293"></a>Kindmark A, Rollman O, Mallmin H, Petrén-Mallmin M, Ljunghall S, Melhus H. Oral isotretinoin therapy in severe acne induces transient suppression of biochemical markers of bone turnover and calcium homeostasis. <i>Acta Derm Venereol</i>. 1998;78(4):266-269. doi:10.1080/000155598441837<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/9689293/pubmed" id="9689293" target="_blank">9689293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25474452">
<a name="25474452"></a>Kızılyel O, Metin MS, Elmas ÖF, Çayır Y, Aktaş A. Effects of oral isotretinoin on lipids and liver enzymes in acne patients. <i>Cutis</i>. 2014;94(5):234-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/25474452/pubmed" id="25474452" target="_blank">25474452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2007670">
<a name="2007670"></a>Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. <i>J Am Acad Dermatol</i>. 1991;24(2 Pt 1):247-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2007670/pubmed" id="2007670" target="_blank">2007670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2747765">
<a name="2747765"></a>Kraft JC, Nau H, Lammer E, et al. Embryonic retinoid concentrations after maternal intake of isotretinoin. <i>N Engl J Med</i>. 1989;321(4):262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2747765/pubmed" id="2747765" target="_blank">2747765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3162101">
<a name="3162101"></a>Lammer EJ, Chen DT, Hoar RM, et al, “Retinoic Acid Embryopathy,” <i>N Engl J Med</i>, 1985, 313(14):837-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/3162101/pubmed" id="3162101" target="_blank">3162101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32107726">
<a name="32107726"></a>Landis MN. Optimizing isotretinoin treatment of acne update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. <i>Am J Clin Dermatol</i>. 2020;21(3):411-419. doi:10.1007/s40257-020-00508-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/32107726/pubmed" id="32107726" target="_blank">32107726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3856419">
<a name="3856419"></a>Larsen GK. Iatrogenic breast discharge with isotretinoin. <i>Arch Dermatol</i>. 1985;121(4):450-451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/3856419/pubmed" id="3856419" target="_blank">3856419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7634848">
<a name="7634848"></a>Lee AG, “Pseudotumor Cerebri After Treatment With Tetracycline and Isotretinoin for Acne,” <i>Cutis</i>, 1995, 55(3):165-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/7634848/pubmed" id="7634848" target="_blank">7634848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21114478">
<a name="21114478"></a>Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. <i>Br J Dermatol</i>. 2011;164(6):1369-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/21114478/pubmed" id="21114478" target="_blank">21114478</a>]</span>
<span class="doi">10.1111/j.1365-2133.2010.10152.x</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7723796">
<a name="7723796"></a>Lotan R, Xu XC, Lippman SM, et al, “Suppression of Retinoic Acid Receptor-Beta in Premalignant Oral Lesions and Its Up-Regulation by Isotretinoin,” <i>N Engl J Med</i>, 1995, 332(21):1405-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/7723796/pubmed" id="7723796" target="_blank">7723796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6238729">
<a name="6238729"></a>Marsden JR, Trinick TR, Laker MF, Shuster S. Effects of isotretinoin on serum lipids and lipoproteins, liver and thyroid function. <i>Clin Chim Acta</i>. 1984;143(3):243-251. doi:10.1016/0009-8981(84)90074-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/6238729/pubmed" id="6238729" target="_blank">6238729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35242965">
<a name="35242965"></a>Marson JW, Baldwin HE. Elevated creatine kinase levels, exercise, and isotretinoin for acne. <i>JAAD Case Rep</i>. 2022;21:133-135. doi:10.1016/j.jdcr.2021.07.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/35242965/pubmed" id="35242965" target="_blank">35242965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519894">
<a name="10519894"></a>Matthay KK, Villablanca JG, Seeger RC, et al, "Treatment of High-Risk Neuroblastoma With Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-<i>cis</i>-Retinoic Acid. Children's Cancer Group," <i>N Engl J Med</i>, 1999, 341(16):1165-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/10519894/pubmed" id="10519894" target="_blank">10519894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11606952">
<a name="11606952"></a>McLane J. Analysis of common side effects of isotretinoin. <i>J Am Acad Dermatol</i>. 2001;45(5):S188-S194. doi:10.1067/mjd.2001.113719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/11606952/pubmed" id="11606952" target="_blank">11606952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12437467">
<a name="12437467"></a>Milstone AM, Milstone LM. Is retinoid-induced osteopenia reversible? <i>Arch Dermatol</i>. 2002;138(11):1516-1517. doi:10.1001/archderm.138.11.1516-a. PMID: 12437467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/12437467/pubmed" id="12437467" target="_blank">12437467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7777014">
<a name="7777014"></a>Mitchell AA, Van Bennekom CM, Louik C, et al, “A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin,” <i>N Engl J Med</i>, 1995, 333(2):101-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/7777014/pubmed" id="7777014" target="_blank">7777014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30858774">
<a name="30858774"></a>Miziołek B, Bergler-Czop B, Stańkowska A, Brzezińska-Wcisło L. The safety of isotretinoin treatment in patients with bone fractures. <i>Postepy Dermatol Alergol</i>. 2019;36(1):18-24. doi:10.5114/ada.2019.82822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/30858774/pubmed" id="30858774" target="_blank">30858774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Myorisan.1">
<a name="Myorisan.1"></a>Myorisan (isotretinoin) [prescribing information]. Lake Forest, IL: Akorn; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management of drug allergy in adults, children and young people. Clinical guideline 183. September 2014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/NICE.1/pubmed" id="NICE.1" target="_blank">NICE.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22508771">
<a name="22508771"></a>Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al, "Ocular Adverse Effects of Systemic Treatment With Isotretinoin," <i>Arch Dermatol</i>, 2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/22508771/pubmed" id="22508771" target="_blank">22508771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27893168">
<a name="27893168"></a>Opel D, Kramer ON, Chevalier M, Bigby M, Albrecht J. Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. <i>Br J Dermatol</i>. 2017;177(4):960-966. doi:10.1111/bjd.15207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/27893168/pubmed" id="27893168" target="_blank">27893168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16681667">
<a name="16681667"></a>Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. <i>Dermatol Surg</i>. 2006;32(4):562-568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/16681667/pubmed" id="16681667" target="_blank">16681667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Owen.1">
<a name="Owen.1"></a>Owen C. Oral isotretinoin therapy for acne vulgaris. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ozdemir.1">
<a name="Ozdemir.1"></a>Ozdemir MA, Kose M, Karakukcu M, Ferahbas A, Patiroglu T, Koklu E. Isotretinoin-induced agranulocytosis. <i>Pediatr Dermatol</i>. 2007;24(4):425-426. doi:10.1111/j.1525-1470.2007.00468.x</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19891242">
<a name="19891242"></a>Papageorgiou NP, Altman A, Shoenfeld Y. Inflammatory bowel disease: adverse effect of isotretinoin. <i>Isr Med Assoc J</i>. 2009 ;11(8):505-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/19891242/pubmed" id="19891242" target="_blank">19891242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32239897">
<a name="32239897"></a>Pasmatzi E, Badavanis G, Kapranos N, Monastirli A, Tsambaos D. Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata. <i>Dermatol Online J</i>. 2020;26(2):13030/qt4cm7b5qs.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/32239897/pubmed" id="32239897" target="_blank">32239897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517990">
<a name="16517990"></a>Passier JL, Srivastava N, van Puijenbroek EP. Isotretinoin-induced inflammatory bowel disease. <i>Neth J Med</i>. 2006;64(2):52-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/16517990/pubmed" id="16517990" target="_blank">16517990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36819385">
<a name="36819385"></a>Pereira-Nunes J, Reis G, Teixeira S, Gaspar NS, Espinheira C, Trindade E. Isotretinoin-induced distal ileitis mimicking Crohn's disease. <i>Cureus</i>. 2023;15(1):e33766. doi:10.7759/cureus.33766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/36819385/pubmed" id="36819385" target="_blank">36819385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21198520">
<a name="21198520"></a>Rademaker M. Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin. <i>Australas J Dermatol</i>. 2010;51(4):248-253. doi:10.1111/j.1440-0960.2010.00657.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/21198520/pubmed" id="21198520" target="_blank">21198520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2738179">
<a name="2738179"></a>Rappaport EB and Knapp M, “Isotretinoin Embryopathy - A Continuing Problem,” <i>J Clin Pharmacol</i>, 1989, 29(5):463-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2738179/pubmed" id="2738179" target="_blank">2738179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2068138">
<a name="2068138"></a>Reynolds CP, Kane DJ, Einhorn PA, et al, “Response of Neuroblastoma to Retinoic Acid <i>In Vitro</i>, and <i>In Vivo</i>,” <i>Prog Clin Biol Res</i>, 1991, 366:203-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2068138/pubmed" id="2068138" target="_blank">2068138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2572922">
<a name="2572922"></a>Reynolds P, Fawcett H, Waldram R, Prouse P. Delayed onset of vasculitis following isotretinoin. <i>Lancet</i>. 1989;2(8673):1216. doi:10.1016/s0140-6736(89)91820-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2572922/pubmed" id="2572922" target="_blank">2572922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22162704">
<a name="22162704"></a>Rosende L, Verea-Hernando MM, de Andrés A, et al. Hypoacusia in a patient treated by isotretinoin. <i>Case Rep Med</i>. 2011;2011:789143. doi:10.1155/2011/789143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/22162704/pubmed" id="22162704" target="_blank">22162704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32683764">
<a name="32683764"></a>Ruiz-Lozano RE, Hernández-Camarena JC, Garza-Garza LA, Bustamante-Arias A, Colorado-Zavala MF, Cardenas-de la Garza JA. Isotretinoin and the eye: a review for the dermatologist. <i>Dermatol Ther</i>. 2020;33(6):e14029. doi:10.1111/dth.14029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/32683764/pubmed" id="32683764" target="_blank">32683764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16405632">
<a name="16405632"></a>Saray Y, Seçkin D. Angioedema and urticaria due to isotretinoin therapy. <i>J Eur Acad Dermatol Venereol</i>. 2006;20(1):118-120. doi:10.1111/j.1468-3083.2005.01350.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/16405632/pubmed" id="16405632" target="_blank">16405632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27885661">
<a name="27885661"></a>Simmons BJ, Chen L, Hu S. Pyogenic granuloma association with isotretinoin treatment for acne. <i>Australas J Dermatol</i>. 2016;57(4):e144-e145. doi:10.1111/ajd.12418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/27885661/pubmed" id="27885661" target="_blank">27885661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sotret.1">
<a name="Sotret.1"></a>Sotret (isotretinoin) [prescribing information]. Jacksonville, FL: Ranbaxy Laboratories Inc.; August 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17276540">
<a name="17276540"></a>Strauss JS, Krowchuk DP, Leyden JJ, et al, "Guidelines of Care for Acne Vulgaris Management," <i>J Am Acad Dermatol</i>, 2007, 56(4):651-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/17276540/pubmed" id="17276540" target="_blank">17276540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163-172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2039732">
<a name="2039732"></a>Taylor AE, Mitchison H. Fatty liver following isotretinoin therapy. <i>Br J Dermatol</i>. 1991;124(5):505-506. doi:10.1111/j.1365-2133.1991.tb00638.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/2039732/pubmed" id="2039732" target="_blank">2039732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29866513">
<a name="29866513"></a>Tejada JT, Torres Yuste R, García Pajares F. Acute pancreatitis secondary to treatment with isotretinoin. <i>Gastroenterol Hepatol</i>. 2019;42(4):256. doi:10.1016/j.gastrohep.2018.04.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/29866513/pubmed" id="29866513" target="_blank">29866513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11816242">
<a name="11816242"></a>ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. <i>Ann Pharmacother</i>. 2002;36(1):130-147. doi:10.1345/aph.1A124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/11816242/pubmed" id="11816242" target="_blank">11816242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25117163">
<a name="25117163"></a>Teo K, Yazdabadi A. Isotretinoin and night blindness. <i>Australas J Dermatol</i>. 2014;55(3):222-224. doi:10.1111/ajd.12107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/25117163/pubmed" id="25117163" target="_blank">25117163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28365528">
<a name="28365528"></a>Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. <i>Eur J Cancer</i>. 2017;77:57-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/28365528/pubmed" id="28365528" target="_blank">28365528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12941114">
<a name="12941114"></a>Türel A, Oztürkcan S, Sahin MT, Türkdogan P. A rare side-effect of systemic isotretinoin treatment: pyogenic granuloma. <i>J Eur Acad Dermatol Venereol</i>. 2003;17(5):609-611. doi:10.1046/j.1468-3083.2003.00620.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/12941114/pubmed" id="12941114" target="_blank">12941114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28542914">
<a name="28542914"></a>Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. <i>Br J Dermatol</i>. 2018;178(1):76-85. doi:10.1111/bjd.15668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/28542914/pubmed" id="28542914" target="_blank">28542914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30504951">
<a name="30504951"></a>Varoglu AO, Aksoy A. Herpes simplex encephalitis and pseudotumour cerebri due to ısotretinoin. <i>J Pak Med Assoc</i>. 2018;68(12):1833-11835.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/30504951/pubmed" id="30504951" target="_blank">30504951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17224928">
<a name="17224928"></a>Veal GJ, Cole M, Errington J, et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group. <i>Br J Cancer</i>. 2007;96(3):424-431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/17224928/pubmed" id="17224928" target="_blank">17224928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22714752">
<a name="22714752"></a>Vieira AS, Beijamini V, Melchiors AC. The effect of isotretinoin on triglycerides and liver aminotransferases. <i>An Bras Dermatol</i>. 2012;87(3):382-387. doi:10.1590/s0365-05962012000300005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/22714752/pubmed" id="22714752" target="_blank">22714752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28624960">
<a name="28624960"></a>Wang JY, French LE, Shear NH, Amiri A, Alavi A. Drug-induced pyoderma gangrenosum: a review. <i>Am J Clin Dermatol</i>. 2018;19(1):67-77. doi:10.1007/s40257-017-0308-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/28624960/pubmed" id="28624960" target="_blank">28624960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(Suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20879881">
<a name="20879881"></a>Yu AL, Gilman AL, Ozkaynak MF, et al, “Anti-GD2 Antibody With GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma,” <i>N Engl J Med</i>, 2010, 363(14):1324-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/20879881/pubmed" id="20879881" target="_blank">20879881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed March 3, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16924051">
<a name="16924051"></a>Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. <i>Arch Dermatol</i>. 2006;142(8):1016-1022. doi:10.1001/archderm.142.8.1016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/16924051/pubmed" id="16924051" target="_blank">16924051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenatane.1">
<a name="Zenatane.1"></a>Zenatane (isotretinoin) [prescribing information]. Princeton, NJ: Dr. Reddy's Laboratories Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17014481">
<a name="17014481"></a>Zhang C and Duvic M, “Treatment of Cutaneous T-Cell Lymphoma With Retinoids,” <i>Dermatol Ther</i>, 2006, 19(5):264-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isotretinoin-pediatric-drug-information/abstract-text/17014481/pubmed" id="17014481" target="_blank">17014481</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13395 Version 473.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
